HomeThe Medicrea Group

The Medicrea Group

MEDICREA® Group Secures New Patents to Protect its Proprietary Platform Technology UNiD ASI

Over the last few years, MEDICREA® Group has had a leading role in revolutionizing the personalized spine surgery. Its disruptive ideas and innovative patient specific technologies have been instrumental in shaping the future spine industry business model associating precise analysis of each patient and pre-op planning expert services to the implants.

Medicrea Partners with Leading National Spine Distributor to Launch Australian Subsidiary

7/10/18: The Company has signed a joint-venture agreement with the Spine division of National Surgical Pty Ltd (“National Surgical”) to introduce the Group’s innovative products and patient-specific technologies in Australia and New Zealand. Other divisions of the National Surgical Businesses will remain unchanged.

Medicrea Receives FDA Clearance for 3D-Printed Titanium Interbody Devices and Introduces AdapTEK™ Surgeon-Adaptive Technology

The Medicrea® Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered device design and manufacturing with UNiD™ Adaptive Spine Intelligence™ (ASI) technology, announced today the Company has received Food and Drug Administration (FDA) clearance for its IB3D™ range of 3D-printed Titanium interbody devices and the introduction of AdapTEK™, its surgeon-adaptive technology.